- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LB PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.12.25 | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 09.12.25 | LB Pharmaceuticals added to Russell 2000 and 3000 indexes | 1 | Seeking Alpha | ||
| 09.12.25 | LB Pharmaceuticals wird in Russell 2000 und Russell 3000 Indizes aufgenommen | 2 | Investing.com Deutsch | ||
| 09.12.25 | LB Pharmaceuticals Inc: LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices | 3 | GlobeNewswire (USA) | ||
| 14.11.25 | LB Pharmaceuticals, Celldex hire commercial chiefs as launch plans ramp up | 5 | FiercePharma | ||
| 13.11.25 | LB PHARMACEUTICALS INC - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | LB Pharmaceuticals appoints Kaya Pai Panandiker as chief commercial officer | 1 | Investing.com | ||
| 12.11.25 | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | 260 | GlobeNewswire (Europe) | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| 06.11.25 | LB Pharmaceuticals Inc GAAP EPS of -$0.61 | 1 | Seeking Alpha | ||
| 06.11.25 | LB Pharmaceuticals meldet Q3-Zahlen und plant Phase-3-Studie für Schizophrenie-Medikament | 1 | Investing.com Deutsch | ||
| 06.11.25 | LB PHARMACEUTICALS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | LB PHARMACEUTICALS INC - 8-K, Current Report | - | SEC Filings | ||
| 14.10.25 | LB Pharmaceuticals beruft Regulierungsexperten vor entscheidender Studienphase | 1 | Investing.com Deutsch | ||
| 14.10.25 | LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs | 1 | Investing.com | ||
| 06.10.25 | LB Pharmaceuticals Inc.: LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms | 1 | GlobeNewswire (USA) | ||
| 06.10.25 | LB Pharmaceuticals stock initiated at Outperform by Leerink Partners | 1 | Investing.com | ||
| 06.10.25 | Leerink Partners startet Coverage für LB Pharmaceuticals mit "Outperform" und hohem Kursziel | 1 | Investing.com Deutsch | ||
| 06.10.25 | LB Pharmaceuticals: Piper Sandler sieht Kurspotenzial von über 400 % | 3 | Investing.com Deutsch | ||
| 06.10.25 | Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating | 1 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MILESTONE PHARMACEUTICALS | 2,015 | -1,71 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| BAYER | 38,200 | 0,00 % | Bayer-Partner Cytokinetics: Top-News abverkauft - Rücksetzer nutzen? | Besser spät als nie: Nach ein paar wenigen Monaten Verzögerung hat die US-amerikanische Biotech-Gesellschaft Cytokinetics am Tag vor Heiligabend in den USA die Zulassung für Myqorzo (Aficamten) zur... ► Artikel lesen | |
| MERCK KGAA | 123,15 | 0,00 % | Merck KGaA: Weichenstellung zum Jahresstart? | 2025 war ein ungewöhnliches Jahr für den deutschen Aktienmarkt: In einige Aktien wurden extrem positive Erwartungen eingepreist, in andere nahezu ein Worst-Case-Szenario. Die Merck KGaA-Aktie gehört... ► Artikel lesen | |
| HARROW | 54,81 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| ASTRAZENECA | 154,35 | 0,00 % | AstraZeneca meldet Gesamtzahl der Stimmrechte von 1,55 Milliarden Aktien | ||
| AQUESTIVE THERAPEUTICS | 6,220 | -3,57 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 80,01 | -4,13 % | Bright Minds Biosciences Inc (2): Bright Minds to discuss BMB-101 phase 2 trial Jan. 6 | ||
| ASTRIA THERAPEUTICS | 12,830 | -0,47 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| NOVO NORDISK | 47,445 | +0,90 % | Gold-Perle, KI-Fantasie und Pharmagigant! Welche Aktie startet 2026 durch? TeamViewer, Novo Nordisk, Laurion Mineral | Die Goldrally ist einfach nicht zu stoppen. Doch die großen Produzenten wie Barrick Mining und Newmont sind bereits gelaufen. Doch es gibt immer wieder unentdeckte Gold-Perlen. Zu diesen gehört Laurion... ► Artikel lesen | |
| GSK | 21,020 | 0,00 % | GSK's Nucala Approved In China For Adult COPD Treatment | LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) announced that China's National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients... ► Artikel lesen | |
| SCHOTT PHARMA | 15,040 | 0,00 % | Schott Pharma: Konsolidierung oder neuer Kursaufschwung? | ||
| DERMAPHARM | 38,300 | 0,00 % | DERMAPHARM HOLDING SE kracht ab - jetzt wird's brutal spannend! | ||
| GILEAD SCIENCES | 101,10 | +0,20 % | AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals | ||
| JOURNEY MEDICAL | 7,130 | -4,30 % | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen |
LB PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 20,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LB PHARMACEUTICALS INC finden Sie auf Wallstreet Online.